Hyaluronic Acid Dosage: What the Skin Trials Use (120–240mg)
Educational summary — not medical advice. Covers ORAL hyaluronic acid dosing only, not HA injections or topical serums, which use entirely different dosing concepts. HA has no established RDA, upper limit, or long-term (6-month+) human safety data at any dose beyond Tashiro 2012's 12-month trial. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
The honest answer
Human skin trials used 120mg/day — Oe 2017 and Hsu 2021, the same 12-week double-blind design, the same research group. Commercial labels commonly offer 100mg, 120mg, or double up to 240mg/day, but no dose-ranging trial exists showing more than 120mg does more for skin. Joint trials used lower, inconsistent doses of different ingredients: 200mg/day of plain HA for 12 months (Tashiro 2012), or only 80mg/day of a different branded ingredient for 3 months (Nelson 2015). There's no RDA or upper limit because HA isn't an essential nutrient.
The dose depends on which outcome you're chasing
Oral HA doesn't have one settled dose the way a vitamin with an RDA does — the verified trials in this evidence base used doses from 80mg to 1g/day (in combo products), and the honest approach is matching the dose to the specific outcome, not defaulting to whatever number is biggest on the shelf. For skin hydration and wrinkles, 120mg/day is genuinely the trial-anchored number: Oe 2017 (n=60, 12 weeks) and Hsu 2021 (n=40, 12 weeks) both used exactly 120mg/day, in the same double-blind, placebo-controlled design, from overlapping Kewpie-affiliated research teams — see the full skin evidence for the funding caveat that goes with this dose every time it's cited. Kawada 2014, a related Kewpie R&D review of two earlier RCTs, doesn't state a specific daily mg figure in its accessible abstract — don't invent one for it.
For joints, the picture is thinner and doesn't reduce to one number. Tashiro 2012 tested 200mg/day of plain oral HA for a full 12 months in knee-OA patients, combined with quadriceps exercise in both arms, and found significantly better symptom scores at months 2 and 4 in patients 70 or younger — weaker in patients over 70. Nelson 2015 tested a completely different ingredient — the branded Oralvisc/Hyal-Joint DS — at only 80mg/day for 3 months, and also found improved pain and function scores. These are two separate trials of two separate ingredients at two separate doses; don't average 200mg and 80mg into a single "the joint dose is X" claim, and don't assume the 120mg skin dose is validated for joints or vice versa.
| Use case | Dose studied | Trial & design |
|---|---|---|
| Skin hydration & wrinkles | 120mg/day, 12 weeks | Oe 2017 (n=60) & Hsu 2021 (n=40), both double-blind, placebo-controlled, same design/group; most authors Kewpie-affiliated |
| Knee osteoarthritis, plain HA | 200mg/day, 12 months | Tashiro 2012 (n=60), double-blind, age-dependent benefit (weaker over 70) |
| Knee osteoarthritis, branded ingredient | 80mg/day, 3 months | Nelson 2015 (n=40), Oralvisc/Hyal-Joint DS, a different ingredient entirely |
| Dry eye (add-on to topical) | Not stated as oral-alone dose | Kim 2019 pilot (n=54 randomized) — oral HA added to topical drops, not standalone |
| Retail commercial range | 50-240mg/serving | No dose-ranging trial exists testing whether 200-240mg outperforms 120mg for any outcome |
How to think about the dose you buy
- 120mg/day is the defensible default if skin hydration/wrinkles is the goal — it's the exact dose behind the strongest, most-replicated (though industry-funded) trials.
- Doubling to 200-240mg/day is untested, not proven better. Many labels sell a 2-capsule serving that does this; no trial has compared it against 120mg to show an advantage.
- Don't use the skin dose for a joint goal, or vice versa. The two joint trials used 200mg and 80mg of different ingredients — neither matches 120mg, and they don't match each other.
- There's no RDA or UL to fall back on. HA isn't an essential nutrient, so unlike vitamin D or magnesium, there's no government reference dose — only the trial doses themselves.
- Pregnant or breastfeeding? No dedicated trial data exists for oral HA in this population — check with a clinician because of the absence of data, not a specific safety signal.
Picks at the skin-trial dose
Full ranking, including the plain-vs-Hyabest-vs-combo breakdown, is on best hyaluronic acid.
Discloses 120mg per serving — the exact skin-trial dose, generic (untested-as-branded) HA.
120mg/serving of the fermentation-derived ingredient Oe 2017 and Hsu 2021 actually used — a higher total bottle price than the plain generics, but slightly cheaper per mg of HA.
As an Amazon Associate we earn from qualifying purchases. Of 4 plain/branded products tracked; ranked by trial-dose match, never commissions.
Frequently asked questions
How much hyaluronic acid should I take per day?
120mg/day is the trial-anchored skin dose (Oe 2017, Hsu 2021). Joint trials used 200mg or 80mg of different ingredients. No RDA/UL exists.
Is a higher dose better for skin?
Untested. No dose-ranging trial has compared 200-240mg against 120mg/day.
Is the skin dose the same as the joint dose?
No. Tashiro 2012 used 200mg plain HA for 12 months; Nelson 2015 used 80mg of a different branded ingredient for 3 months — neither matches the skin dose or each other.
Is there an RDA or upper limit?
No. HA isn't an essential nutrient, so there's no government reference dose — only the trial doses themselves.
Related
- Hyaluronic acid: what it is & who it's for
- Best hyaluronic acid — plain vs Hyabest vs BioCell, ranked
- Hyaluronic acid for skin hydration & wrinkles
- Does oral HA actually reach your skin?
Sources
- Oe M, et al. "Oral hyaluronan relieves wrinkles: a double-blinded, placebo-controlled study over a 12-week period." Clin Cosmet Investig Dermatol. 2017. PMID: 28761365 (120mg/day).
- Hsu TF, et al. "Oral Hyaluronan Relieves Wrinkles and Improves Dry Skin: A 12-Week Double-Blinded, Placebo-Controlled Study." Nutrients. 2021. PMID: 34203487 (120mg/day).
- Tashiro T, et al. "Oral administration of polymer hyaluronic acid alleviates symptoms of knee osteoarthritis." The Scientific World Journal. 2012. PMID: 23226979 (200mg/day, 12 months).
- Nelson FR, et al. "The effects of an oral preparation containing hyaluronic acid (Oralvisc) on obese knee osteoarthritis patients." Rheumatol Int. 2015. PMID: 24899570 (80mg/day, 3 months).
- Full product dataset: /hyaluronic-acid/cost-by-brand.json (CC BY 4.0).